3SBIO (01530) released its mid-term results, with a net profit attributable to shareholders of 1.147 billion yuan, a decrease of 15.58% year-on-year.

3SBIO (01530) released its mid-year results for 2026, with the group achieving revenue of 4.526 billion yuan, an increase of 3.91% year-on-year; the profit attributable to equity shareholders was 1.147 billion yuan, a decrease of 15.58% year-on-year; basic earnings per share were 0.45 yuan. Looking back at the first half of 2026, the group actively responded to the policy requirements for innovative development, continuously focusing on the research and development of innovative drugs. During the reporting period, the construction of the groups R&D system accelerated, expanding the workforce to approximately 840 people, with 25 key projects currently under development. The group has achieved full coverage of major targets in the autoimmune field and laid out the next-generation technical routes such as T-cell engagers (TCE) and In-Vivo CAR-T; in the oncology field, it has established new drug formats including multi-specific antibodies, antibody-drug conjugates (ADC), and TCE, and is making forward-looking layouts in emerging modalities such as R&D, gene and cell therapy through investment and collaboration. The group emphasizes AI-assisted drug development and has built professional models for drug development using its own data, applied in various stages including candidate molecule selection and clinical development. In the commercialization sector, the groups independently developed innovative drugs, Yisaite (Anmuchi monoclonal antibody injection) and Xinbiao (Roxadustat injection), were approved for market launch in the first half of 2026, covering more patients with unmet clinical needs; meanwhile, sales of existing drugs faced temporary pressure from medical insurance payment reforms and deepening centralized procurement, resulting in fluctuations in traditional varieties' hospital sales. The group is working to maintain the market position of its core products through professional compliance in market access and academic promotion. Looking ahead to the second half of 2026, the group will continue to strengthen its efforts in three main areas: commercialization, new drug development, and external collaboration. In terms of commercialization, it will focus on building an expert network for Yisaite in the psoriasis field, facilitating the iterative treatment plans for Xinbiao in dialysis centers, and synergistically promoting Teaiseng alongside Teibiao, creating a complete product matrix for thrombocytopenia. The group also expects more new products to launch in the second half of 2026. In terms of R&D strategy, the group will continue to advance the development of clinical late-stage pipeline products centered around core therapeutic areas such as oncology, immunology, nephrology, metabolism, and dermatology, enhance early-stage research capabilities, diversify innovative molecule types, and accelerate the pace of molecule development. In terms of external collaboration, the group will continue to implement a dual-track strategy of independent research and global cooperation, actively seeking opportunities to collaborate with multinational corporations on self-developed pipelines, while widely assessing merger and acquisition and introduction opportunities in the innovative drug sector to supplement pipeline assets. Based on over 30 years of industry experience, the group will continue to uphold the mission of "making innovative biologics accessible," calmly respond to short-term operational fluctuations, and steadfastly invest in long-term innovation capability building, creating lasting value for patients and shareholders.